#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic myeloid leukaemia Uveitis Hypophosphatasia Liposarcoma Central nervous system neoplasm Neurodegenerative disorder Rhabdomyosarcoma recurrent Krabbe's disease KBG syndrome Osteomyelitis Testicular leiomyosarcoma Cardiac amyloidosis Autoimmune disorder Superficial vein thrombosis Erythema multiforme More trials…

    Learn about Rare Diseases

    Krabbe’s disease – Basic Information Phenylketonuria – Trials in Disease Waldenstrom’s macroglobulinaemia Mantle cell lymphoma refractory KBG syndrome – Diagnostics Biotinidase deficiency Epidermolysis bullosa – Trials in Disease Sarcoma – Basic Information Factor IX deficiency – Trials in Disease Osteosarcoma metastatic – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Teicoplanin Pamapimod Valganciclovir Hydrochloride ZIGAKIBART Docetaxel Levomepromazine Hydrochloride Alectinib Hydrochloride Etoposide Phosphate Pyrimethamine Nefopam Prednisolone Sodium Succinate Neomycin Sulfate Esomeprazole Ramipril Omalizumab Ads-010 19Cp02 Varnimcabtagene Autoleucel Pehero VAMIFEPORT TRIHYDROCHLORIDE More therapies…

    Learn about Your Condition

    Myotonic dystrophy Vulvovaginal pain Immunodeficiency congenital Trigeminal neuralgia Microscopic polyangiitis Open angle glaucoma Transplantation complication Torticollis Neuropathy peripheral Crohn's disease Diabetic gastroparesis Progressive multiple sclerosis Neck pain Glomerulonephritis membranous Medullary thyroid cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer metastatic

  • A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Belgium Bulgaria Czechia Finland France Germany +6

  • Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • LUXDEGALUTAMIDE
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Gozetotide
    Austria Czechia France Germany Italy The Netherlands +1

  • Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    • Prostate cancer
    Investigated Drugs:
    • 4-((3-((5,6-Dihydro-2-(Trifluoromethyl)(1,2,4)Triazolo(1,5-A)Pyrazin-7(8H)-Yl)Carbonyl)-4-Fluorophenyl)Methyl)-1(2H)-Phthalazinone
    • Abiraterone Acetate
    • Prednisone
    Belgium Czechia France Hungary Poland Spain

  • Study of PF-06821497 with Enzalutamide for Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    • Dexamethasone
    Czechia France Germany Greece Hungary Italy +5

  • Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Degarelix
    Belgium Bulgaria France Italy Lithuania Poland +1

  • Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Radium Ra 223 Dichloride
    • Dexamethasone Phosphate
    • Dexamethasone Sodium Phosphate
    Italy
Previous Page
1 … 3 4 5 6 7 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!